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Abstract
This study aimed to determine whether telomere length (TL) is a marker of cancer risk or genetic status amongst two
cohorts of BRCA1 and BRCA2 mutation carriers and controls. The first group was a prospective set of 665 male BRCA1/2
mutation carriers and controls (mean age 53 years), all healthy at time of enrolment and blood donation, 21 of whom have
developed prostate cancer whilst on study. The second group consisted of 283 female BRCA1/2 mutation carriers and
controls (mean age 48 years), half of whom had been diagnosed with breast cancer prior to enrolment. TL was quantified by
qPCR from DNA extracted from peripheral blood lymphocytes. Weighted and unweighted Cox regressions and linear
regression analyses were used to assess whether TL was associated with BRCA1/2 mutation status or cancer risk. We found
no evidence for association between developing cancer or being a BRCA1 or BRCA2 mutation carrier and telomere length. It
is the first study investigating TL in a cohort of genetically predisposed males and although TL and BRCA status was
previously studied in females our results don’t support the previous finding of association between hereditary breast cancer
and shorter TL.
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Introduction
Telomeres are hundreds to thousands of nucleotide repeats
(TTAGGG) located at eukaryotic chromosome ends [1], without
which genetic material would be lost every time a cell divides. The
capacity of a cell to replicate is limited by TL; when telomeres
become critically short, cell cycle arrest, senescence and apoptosis
is signalled [2]. If this process fails for some reason and cell division
persists despite the telomeres being too short then chromosomal
instability results with end-to-end fusion of chromosomes [3].
Many factors are known to be associated with reduced TL, a
primary factor being age with peripheral blood lymphocyte
telomeres shortening by, on average, 41 base pairs per year [4].
Various studies have shown other factors associated with TL
including smoking [5], inflammatory processes, socio-economic
status, diet [6], BMI [7], diabetes mellitus [8], coronary artery
disease, ulcerative colitis [9], physical activity and psychological
stress [10].
Conflicting results have come from studies investigating links
between cancer risk and TL. A recent meta-analysis demonstrated
an association between shorter TL and increased cancer risk in
studies of bladder cancer, oesophageal cancer, gastric cancer, head
and neck cancer, ovarian cancer and overall incident cancers [11].
There was inconsistency in studies looking at association between
TL and risk of non-Hodgkins lymphoma, breast cancer, lung
cancer and colorectal cancer; the single study in prostate cancer
was negative. That study looked at leukocyte TL as a marker of
prostate cancer risk within the participants of the Prostate, Lung,
Colorectal and Ovarian (PLCO) screening trial [5]. In the main
analysis prostate cancer cases and controls did not differ with
respect to TL, although there was a trend to decreased risk of
prostate cancer with shorter TL once adjusted for smoking status.
Interestingly, in individuals with a family history of prostate cancer
shorter telomeres seemed to be associated with increased prostate
cancer risk, although again this did not reach significance.
Published studies investigating breast cancer risk and TL have
produced conflicting results, with two studies showing a significant
association between longer telomeres and breast cancer risk
[12,13] but other studies showing no association, or association
only in sub-groups [14–16]. A potential confounding factor is
whether such studies are undertaken retrospectively or prospec-
tively, with both chemotherapy and radiotherapy having the
potential to affect peripheral blood lymphocyte TL [17,18]. A
recently published prospective study of over 47000 individuals
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e86659
followed-up for 20 years found an association between shorter
telomere length and survival once diagnosed with cancer, but no
association with cancer risk [19].
Both prostate and breast cancer have a heritable component to
their aetiology [20]; much of the heritability of prostate cancer is
thought to be due to the inheritance of multiple low penetrance
susceptibility single nucleotide polymorphisms (SNPs), but inher-
itance of rarer BRCA1 or BRCA2 gene mutations is known to
increase breast cancer risk and to a lesser extent prostate cancer
risk. A recent paper demonstrated reduced TL in breast cancer
patients who carried mutations in the BRCA1/2 genes compared
with sporadic breast cancer cases [21]. The same group also
demonstrated shorter TL in both sporadic and hereditary ovarian
cancer compared with controls [22]; no similar investigation has
been carried out in male BRCA1/2 mutation carriers with prostate
cancer. Preclinical studies have suggested that BRCA2 has a role
in telomere stabilisation [23–25]. Also some studies have shown
that BRCA1 expression may have an effect on TL [26,27],
although the evidence is not as strong as for BRCA2. Both papers
from Delgado-Martinez et al. included larger numbers of cases
with mutations in BRCA1 than in BRCA2. In this study, we have
analysed TL in two distinct cohorts; a retrospective female cohort
of BRCA1/2 mutation carriers and their non-carrier relatives, a
proportion of whom have a previous diagnosis of breast cancer,
and a prospective male cohort of BRCA1/2 mutation carriers and
controls, all cancer free at time of blood donation, a proportion of
whom have developed prostate cancer during follow-up. Although
BRCA1/2 mutations are predominantly associated with breast and
ovarian cancer risk the risk of prostate cancer is increased in males,
and TL may be useful for risk stratification. The association
between genetic status and TL should not be affected by
retrospective or prospective nature of the studies.
Materials and Methods
Ethics statement
IMPACT and RMH Carrier Clinic Set were approved by the
National Health Service, Health Research Authority, National
Research Ethics Service, London (reference numbers 05/
MRE07/25 and 05/Q0801/7 respectively); all participants gave
informed written consent.
Study cohorts
1. IMPACT set. TL was measured in blood DNA from male
BRCA1 and BRCA2 mutation carriers and controls from the
IMPACT study (Identification of Men with a genetic predisposi-
tion to ProstAte Cancer: Targeted Screening in BRCA1/2
mutation carriers and controls), an international study set up to
evaluate PSA screening in male BRCA1 and BRCA2 carriers. To
be eligible, men must be either a BRCA1 or BRCA2 mutation
carrier or from a family harbouring the gene mutation but have
tested negative themselves (controls). All men were aged between
40 and 69 years with no history of prostate cancer, and no
previous biopsy for raised PSA. The recruits gave a blood sample
for DNA extraction at enrolment and underwent annual PSA
screening with PSA.3.0 ng/ml triggering a diagnostic prostate
biopsy. A total of 240 BRCA1 and 207 BRCA2 male mutation
carriers plus 218 controls were used in a prospective study of TL.
As only four controls developed prostate cancer these were
removed from the analyses i.e. the association between TL and
prostate cancer risk was not tested in the non-carriers. Smoking
status was divided into four categories (no, ex-smoker, yes
currently, not known) with ‘no’ being the baseline category in
the analyses.
2. Royal Marsden Hospital (RMH) Carrier Clinic
set. BRCA1/2 mutation carriers and controls (non-carrier family
members) were recruited to the RMH Carrier Clinic set, in which
they donate blood samples for DNA extraction at enrolment. To
be eligible, recruits must be of known BRCA1/2 mutation status
and d over 18 years. Only samples from female recruits were used
for the TL analysis. A total of 131 BRCA1 and 109 BRCA2 female
Figure 1. Correlation between relative TL of unaffected men in
IMPACT set (n = 644) and age at blood-draw (r =20.164,
p,0.001).
doi:10.1371/journal.pone.0086659.g001
Table 1. Characteristics of IMPACT and RMH Carrier Clinic recruits.
IMPACT RMH Carrier Clinic set
N 665 283
Mean age (range) 53.0 (40–69) 48.0 (20–78)
BRCA1 mutation carriers 240 131
BRCA2 mutation carriers 207 109
Controls 214 43
Affected by cancer (% of BRCA1/2 mutation carriers affected) 21 (4.7%) 124 (51.7%)
Mean age at cancer diagnosis (range) 53.1 (41–68) 42.7 (23–69)
doi:10.1371/journal.pone.0086659.t001
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mutation carriers plus 43 controls were used in a retrospective
study of TL. One person was found to have mutations in both
genes so was included in the analyses as a BRCA1 mutation carrier.
Telomere length quantification
Using quantitative real-time PCR, relative TL was measured in
DNA commercially extracted from peripheral blood lymphocytes.
20 ng of DNA per sample was dried down in 384 plates. Each
plate also contained serial dilutions of DNA giving 100ng DNA to
1ng DNA in duplicate to allow for efficiency calculations
(efficiency = 10(21/slope)) and three reference DNAs were added
to each plate. All samples were tested in duplicate. The primer
sequences quantifying TL were: 59 CGGTTTGTTTGGGTTT-
GGGTTTGGGTTTGGGTTTGGGTT 39 (TEL_F) and 59
GGCTTGCCTTACCCTTACCCTTACCCTTACCCT-
TACCCT 39 (TEL_R) (Integrated DNA Technologies) [28].
The single copy gene used as a control (CON) was 36B4 (gene
that encodes acidic ribosomal phosphoprotein) which had the
advantage that it could be amplified under the same PCR
conditions as the TEL, thus reducing the risk of inter-plate
variation between the TEL and CON reactions. The 36B4 primer
sequences were 59 CAGCAAGTGGGAAGGTGTAATCC 39
(36B4_F) and 59 CCATTCTATCATCAACGGGTACAA 39
(36B4_R) (Integrated DNA Technologies) [29]. 5 ml of 26 power
SYBR Green PCR Master Mix (KapaBiosystems) and 4 ml H2O
were added to each well; samples were left for two hours in the
dark at 4uC for resuspension of DNA. The thermal cycling profile
proceeded as follows: 10 minutes at 95uC followed by 35 cycles of
95uC for 15 seconds, 54uC for 2 minutes and 72uC for 15 seconds
as used previously [21]. The qPCR amplification was performed
using Applied Biosystems 7900HT real-time PCR system and the
RQ Manager software version 1.2 was used to determine the
relative TL.
The Ct value, defined as the number of PCR cycles taken for
the amplified DNA to cross a predefined threshold, was used to
calculate the telomere repeat copy number to single copy gene
copy number ratio (T/S) using T/S = 22DCt. The relative TL was
determined by normalizing the ratio (T/S) of each sample to the
calibrator DNA to standardise sample values across all reaction
plates. For ease of data manipulation the natural log was taken of
this value. Three internal controls DNA were run in each plate.
For each run, PCR efficiency and internal controls values were
monitored.
Statistical analysis
Age. Linear regression analysis was used in both sets to assess
the association between age and TL. Correlation was assessed
using Spearman’s correlation.
Carrier status. Linear regression analyses were used to
correlate TL with carrier status. The analyses were adjusted for
age at enrolment and smoking status in the IMPACT set, and
adjusted for age in the RMH Carrier Clinic set (smoking status was
not available for the female set); analyses were carried out using a
robust variance estimation to account for several individuals
coming from the same family. The joint analysis of both BRCA1
and BRCA2 mutation carriers was stratified by gene.
Cancer Risk. Hazard ratios (HR) for prostate cancer
according to TL in the IMPACT study were estimated using
Cox regression, adjusting for smoking status and age at blood
draw. Age at enrolment was used as the left-censor age.
Women in the RMH Carrier Clinic set were recruited on the
basis of having a BRCA1/2 mutation or having a relative with such
a mutation. A diagnosis of breast cancer, particularly at a young
age, would very often be part of the criteria for genetic testing, and
since women with breast cancer prior to recruitment were not
excluded it is likely that cases of breast cancer would be
overrepresented in the set. HRs from a standard Cox regression
approach would be potentially biased, so we instead used a
weighted cohort Cox regression analysis [30]. Individuals were
weighted such that the observed breast cancer incidence rates in
each age interval in the study samples were consistent with
established external estimates of cancer risk among BRCA1 and
BRCA2 mutation carriers in that age interval. As the study group
was small and the majority of individuals (94%) were aged less
than 60 years, weights were calculated using the post-1950
incidence rates. The analyses were carried out using a robust
variance estimation to account for several individuals coming from
the same family and were adjusted for age at blood draw. The
joint analysis of both BRCA1 and BRCA2 mutation carriers was
stratified by gene and the BRCA1 mutation incidence rates were
used to calculate the weights.
Table 2. Association between BRCA1 or BRCA2 mutation status and mean relative TL in the IMPACT study, adjusting for age and
smoking status, and in the RMH Carrier Clinic Set, adjusting for age.
Cohort Genetic status n Adjusted Mean rel TL (se) P vs non-carriers
IMPACT set BRCA1/2 Non-carrier 214 1.17 (0.024) -
BRCA1 Carriers 240 1.16 (0.226) 0.638
BRCA2 Carriers 207 1.19 (0.024) 0.768
All BRCA1&2 Carriers 447 1.17 (0.017) 0.900
RMH Carrier Clinic Set (all samples) BRCA1/2 Non-carrier 43 1.69 (0.082) -
BRCA1 Carriers 131 1.69 (0.041) 0.969
BRCA2 Carriers 110 1.65 (0.043) 0.653
All BRCA1&2 Carriers 241 1.67 (0.030) 0.815
RMH Carrier Clinic Set (unaffected only) BRCA1/2 Non-carrier 43 1.72 (0.079) -
BRCA1 Carriers 65 1.70 (0.049) 0.809
BRCA2 Carriers 50 1.76 (0.049) 0.746
All BRCA1&2 Carriers 115 1.72 (0.037) 0.987
doi:10.1371/journal.pone.0086659.t002
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Results
IMPACT set
Participants’ characteristics are summarised in Table 1. There
was an approximately equal division of men between BRCA1
mutation carriers, BRCA2 mutation carriers and controls; 21 men
had prostate cancer. The expected negative correlation between
TL in and age was observed among those unaffected by cancer
(r =20.164, p,0.001), see Figure 1.
We investigated if there was any association between BRCA
mutation status and TL, analysing BRCA1 and BRCA2 mutation
carriers separately and combined, and found no significant
association, see Table 2. There was .90% power to detect a
difference in TL of 10%.
Of the 240 BRCA1 mutation carriers, 5 developed prostate
cancer, and of the 207 BRCA2 mutation carriers, 16 individuals
were diagnosed. Statistical analysis showed no association between
TL and prostate cancer risk. Hazard ratios (HR), 95% confidence
intervals and P-values for the association of telomere lengths with
prostate cancer risk are shown in Table 3.
RMH Carrier Clinic set
The participants’ characteristics of this cohort are summarised
in Table 1; approximately half the subjects had been affected by
cancer. There was a negative correlation between TL and age
among those unaffected by cancer (r =20.126) as shown in
Figure 2, this does not quite reach significance (p = 0.078);
however when a linear regression model was used to assess the
impact of age on TL this was found to be significant (p = 0.001).
Stratifying by cancer status, we found no significant association
between BRCA mutation status and TL, either considering BRCA1
and BRCA2 mutation carriers as separate groups, or as a combined
set, see Table 2, however the power to detect a 10% difference was
only 42%.
TL was compared in BRCA1/2 mutation carriers with cancer
and unaffected BRCA1/2 mutation carriers. Statistical analysis
showed no association between TL and breast cancer risk. Hazard
ratios (HR), 95% confidence levels and P-values for the association
of telomere lengths with breast cancer risk are shown in Table 3.
Discussion
To our knowledge this is the first published study of TL in male
BRCA1/2 mutation carriers and the largest published study in
female BRCA1/2 mutation carriers. We found no association
between TL and BRCA1/2 mutation status in either of the two
cohorts. Martinez-Delgado et al [21] demonstrated shorter TL in
a smaller set of affected BRCA1 mutation carriers (n = 45), BRCA2
mutation carriers (n = 48) and healthy controls (n = 276); there was
no difference between affected individuals with a family history but
no mutation in BRCA1/2 (n = 105) and the healthy control group.
However, it is not clear whether the effect was due to the BRCA1/
2 mutation status or their cancer status, or indeed previous cancer
treatment, as both chemotherapy and radiotherapy have been
shown to affect TL [17,18]. In order to prevent the potential
confounding effect of high cancer rates we performed our analyses
of the association between genetic status and TL separately for the
affected and unaffected individuals. However this reduced the
numbers in the analysis, increasing the chance of a false negative
finding. A recently opened study is recruiting unaffected BRCA1/2
mutation carriers to explore any relationship between TL (plus a
variety of metabolic and lifestyle factors) and breast cancer risk,
and will avoid the compounding factors such as treatment effects
which may bias the retrospective studies [31].
In the male set it is important that the individuals underwent
screening for prostate cancer, as men in the general population are
not routinely screened and prostate cancer is a condition which
can go undiagnosed for many years. BRCA1/2 mutation carriers
are at increased risk of developing prostate cancer and therefore,
Table 3. Hazard ratios for prostate cancer in the IMPACT study, (Cox regression analyses) and for breast cancer in the RMH study,
(weighted retrospective Cox regression analyses), by BRCA1/2 mutation status.
Cohort Genetic status
Number with
cancer
Number without
cancer HR 95% CI P
IMPACT set BRCA1 mutation carriers 5 235 1.00 0.085–11.7 0.999
BRCA2 mutation carriers 16 191 0.493 0.103–2.36 0.376
All mutation carriers 21 426 0.658 0.188–2.30 0.512
RMH Carrier Clinic Set BRCA1 mutation carriers 66 65 1.063 0.448–2.53 0.889
BRCA2 mutation carriers 60 50 0.467 0.209–1.04 0.063
All mutation carriers 126 115 0.782 0.449–1.36 0.384
doi:10.1371/journal.pone.0086659.t003
Figure 2. Correlation between relative TL in unaffected women
in the RMH Carrier Clinic set (n =159) and age at blood-draw
(r =20.126, p=0.078).
doi:10.1371/journal.pone.0086659.g002
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despite the limitations of screening, an unscreened cohort would
be more likely to have cases of undiagnosed cancer with potential
for bias.
Within the IMPACT set there was no difference in TL in
BRCA1/2 mutation carriers with prostate cancer versus cancer
free BRCA1/2 mutation carriers. This finding is in keeping with
Mirabello et al [5] who did not find a difference in TL in a
retrospective study of men with prostate cancer versus healthy
controls. However, they did find a trend towards shorter TL in
those with a family history of prostate cancer, which, in
combination with the fact that TL appeared to have an effect
on breast cancer risk in female BRCA1/2 mutation carriers [21],
had driven our investigation into association of TL with prostate
cancer risk in male BRCA1/2 mutation carriers. It should be noted
that in this study there were only 21 cases with cancer and mean
follow-up time was 46 months. Within the IMPACT study,
recruits undergo biopsy based on PSA screening with a
PSA.3.0 ng/ml triggering biopsy. Given the known limitations
of PSA screening [32], it may be that some recruits harbour occult
prostate cancer, or some are yet to develop cancer and with
further follow-up there is the possibility that a difference in TL
may be appreciated.
In the retrospective female BRCA1/2 mutation carrier set, we
found no significant difference in TL between those with breast
cancer and cancer-free controls. There has been a discordance in
previously published studies of TL in association with sporadic
breast cancer, with some studies showing association and others
not [14]. The only published study quantifying TL in individuals
with breast cancer who carry BRCA1/2 mutations and individuals
with sporadic breast cancer showed an association between shorter
telomeres in those affected by hereditary cancer, but not in those
affected by sporadic breast cancer. In this study, we compared
BRCA1/2 mutation carriers with cancer and BRCA1/2 mutation
carriers without cancer, predominantly to investigate the possibil-
ity of using TL as a method of risk stratification amongst BRCA1/2
mutation carriers. We found no evidence that TL could be useful
in this way.
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